Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice

摘要: Abstract Introduction Tumor genotyping using single gene assays (SGAs) is standard practice in advanced non-small-cell lung cancer (NSCLC). We evaluated how the introduction of next generation sequencing (NGS) into day-to-day clinical altered therapeutic decision-making. Methods Clinicopathologic data, tumor genotype, and decisions were retrospectively compiled over 6 months following NGS assay use at our institution 82 patient-tumor samples (7 by primary NGS, 22 sequential SGAs followed 53 SGAs). Results identified abnormalities 34 samples, all patients with EGFR -mutated or ALK -rearranged tumors received approved tyrosine kinase inhibitors (TKIs) consented for trials. was more commonly requested , KRAS -negative ( p FGFR1 ); had other genomic events (all TP53 mutations). In no cases =0.0538 when compared to ACs). Conclusions Targeted can identify a significant number therapeutically-relevant driver ACs; particularly never light smokers. For SC cancers, less likely alter current practice. Further research cost effectiveness optimal improved provider training oncology are warranted.